All Stories

  1. Low dose IL-2 administration prevents but fails to treat experimental autoimmune anti-myeloperoxidase glomerulonephritis
  2. Both Classical and Non-Classical Monocytes Patrol Glomerular Capillaries and Promote Acute Glomerular Inflammation
  3. Relationships between patient and physician global assessments in anti-neutrophil cytoplasmic antibody-associated vasculitis
  4. Neutralizing the IL-7Rα limits injury in experimental ANCA-associated glomerulonephritis
  5. The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosus
  6. Challenges for trainee physician–scientists during their PhD candidature: a cross‐sectional study
  7. Variation in approaches to acute ANCA‐associated vasculitis in Australia and New Zealand: rituximab, plasma exchange and glucocorticoids
  8. Hematuria in Podocytopathies
  9. The plethora of immunomodulatory drugs: opportunities for immune-mediated kidney diseases
  10. The five types of glomerulonephritis classified by pathogenesis, activity and chronicity (GN-AC)
  11. Glomerulonephritis: immunopathogenesis and immunotherapy
  12. Toll-like Receptor 9 Induced Dendritic Cell Activation Promotes Anti-Myeloperoxidase Autoimmunity and Glomerulonephritis
  13. T‐cell receptor αβ+ double‐negative T cells in the kidney are predominantly extravascular and increase in abundance in response to ischemia–reperfusion injury
  14. Identifying Antigen-Specific T Cells in ANCA-Associated Vasculitis: A Glimpse of the Future?
  15. Immunoaging within the kidney via injury-associated tertiary lymphoid tissue
  16. Case of vertebral fracture with nephrolithiasis and hypocitraturia
  17. Tetraspanin CD53 modulates lymphocyte trafficking but not systemic autoimmunity in Lyn‐deficient mice
  18. Immune cell behaviour and dynamics in the kidney — insights from in vivo imaging
  19. Ageing enhances cellular immunity to myeloperoxidase and experimental anti-myeloperoxidase glomerulonephritis
  20. The impact of antineutrophil cytoplasmic antibody‐associated vasculitis on employment and work disability in an Australian population
  21. Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease
  22. Anti-CD20 mAb-Induced B Cell Apoptosis Generates T Cell Regulation of Experimental Myeloperoxidase ANCA-Associated Vasculitis
  23. ANCA-associated vasculitis
  24. Experimental Antiglomerular Basement Membrane GN Induced by a Peptide from Actinomyces
  25. Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers
  26. A plasmid-encoded peptide from Staphylococcus aureus induces anti-myeloperoxidase nephritogenic autoimmunity
  27. Apoptotic Cell–Induced, Antigen-Specific Immunoregulation to Treat Experimental Antimyeloperoxidase GN
  28. Standardized Outcomes in Nephrology—Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease
  29. Functional rare and low frequency variants in BLK and BANK1 contribute to human lupus
  30. HLA-DR15-specific inhibition attenuates autoreactivity to the Goodpasture antigen
  31. The renal draining lymph nodes in acute inflammatory kidney disease
  32. Platelet retention in inflamed glomeruli occurs via selective prolongation of interactions with immune cells
  33. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
  34. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
  35. Intrarenal Toll-like receptor 4 and Toll-like receptor 2 expression correlates with injury in antineutrophil cytoplasmic antibody-associated vasculitis
  36. Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus
  37. Goodpasture's autoimmune disease — A collagen IV disorder
  38. Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus
  39. HLA and kidney disease: from associations to mechanisms
  40. Formyl peptide receptor activation inhibits the expansion of effector T cells and synovial fibroblasts and attenuates joint injury in models of rheumatoid arthritis
  41. CD8+ cells and glomerular crescent formation: outside-in as well as inside-out
  42. Chimeric antigen receptor T (CAR T) cells: another cancer therapy with potential applications in kidney disease and transplantation?
  43. OX40 ligand is inhibitory during the effector phase of crescentic glomerulonephritis
  44. C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis
  45. Effector CD4+ T cells recognize intravascular antigen presented by patrolling monocytes
  46. The C3aR promotes macrophage infiltration and regulates ANCA production but does not affect glomerular injury in experimental anti-myeloperoxidase glomerulonephritis
  47. Regulatory T cells in renal disease
  48. Inflammasomes in the Kidney
  49. Immune-mediated kidney disease in 2017: Progress in mechanisms and therapy for immunological kidney disease
  50. Renal Dendritic Cells: The Long and Winding Road
  51. Pathogenic Role for γδ T Cells in Autoimmune Anti-Myeloperoxidase Glomerulonephritis
  52. ANCA-Associated Vasculitis: Pathogenesis, Models, and Preclinical Testing
  53. Chyluria: When is proteinuria ‘not proteinuria’?
  54. Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells
  55. Activated Renal Dendritic Cells Cross Present Intrarenal Antigens After Ischemia-Reperfusion Injury
  56. Imaging Leukocyte Responses in the Kidney
  57. In Vivo Imaging of Inflamed Glomeruli Reveals Dynamics of Neutrophil Extracellular Trap Formation in Glomerular Capillaries
  58. Interleukin-17RA Promotes Humoral Responses and Glomerular Injury in Experimental Rapidly Progressive Glomerulonephritis
  59. From bench to pet shop to bedside? The environment and immune function in mice
  60. Induced regulatory T cells are phenotypically unstable and do not protect mice from rapidly progressive glomerulonephritis
  61. The NLRP3 inflammasome in kidney disease and autoimmunity
  62. Patrolling monocytes promote intravascular neutrophil activation and glomerular injury in the acutely inflamed glomerulus
  63. CD8 + T Cells Effect Glomerular Injury in Experimental Anti-Myeloperoxidase GN
  64. The Players: Cells Involved in Glomerular Disease
  65. Erratum: Corrigendum: Multiphoton imaging reveals a new leukocyte recruitment paradigm in the glomerulus
  66. Biologics for the treatment of autoimmune renal diseases
  67. Regulatory T cells in immune-mediated renal disease
  68. Neutrophil-Mediated Regulation of Innate and Adaptive Immunity: The Role of Myeloperoxidase
  69. Can we target IL-17A and IL-23 in immune kidney disease?
  70. Renal participation of myeloperoxidase in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis
  71. Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis
  72. Mast Cell Stabilization Ameliorates Autoimmune Anti-Myeloperoxidase Glomerulonephritis
  73. Endogenous Toll-Like Receptor 9 Regulates AKI by Promoting Regulatory T Cell Recruitment
  74. Suppression of Autoimmunity and Renal Disease in Pristane-Induced Lupus by Myeloperoxidase
  75. Myeloperoxidase Peptide-Based Nasal Tolerance in Experimental ANCA-Associated GN
  76. Mouse Models of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
  77. FMS-Like Tyrosine Kinase 3 Ligand Treatment Does Not Ameliorate Experimental Rapidly Progressive Glomerulonephritis
  78. CX3CR1 Reduces Kidney Fibrosis by Inhibiting Local Proliferation of Profibrotic Macrophages
  79. FcγRIIB regulates T-cell autoreactivity, ANCA production, and neutrophil activation to suppress anti-myeloperoxidase glomerulonephritis
  80. T Cell Mediated Autoimmune Glomerular Disease in Mice
  81. Regulatory T Cells Dynamically Regulate Selectin Ligand Function during Multiple Challenge Contact Hypersensitivity
  82. Four pediatric patients with autosomal recessive polycystic kidney disease developed new-onset diabetes after renal transplantation
  83. Glomerulonephritis Induced by Heterologous Anti-GBM Globulin as a Planted Foreign Antigen
  84. Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes
  85. Omeprazole-induced acute interstitial nephritis: A possible Th1-Th17-mediated injury?
  86. Endogenous Tim-1 promotes severe systemic autoimmunity and renal disease MRL-Faslpr mice
  87. Innate IL-17A–Producing Leukocytes Promote Acute Kidney Injury via Inflammasome and Toll-Like Receptor Activation
  88. Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane
  89. Dendritic cells in progressive renal disease: some answers, many questions
  90. Histopathologic and Clinical Predictors of Kidney Outcomes in ANCA-Associated Vasculitis
  91. Neutrophil myeloperoxidase regulates T-cell-driven tissue inflammation in mice by inhibiting dendritic cell function
  92. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis
  93. Myeloperoxidase (MPO)-specific CD4+ T cells contribute to MPO-anti-neutrophil cytoplasmic antibody (ANCA) associated glomerulonephritis
  94. The HLA-DRB1*15:01-Restricted Goodpasture's T Cell Epitope Induces GN
  95. Thymic Deletion and Regulatory T Cells Prevent Antimyeloperoxidase GN
  96. Proteolysis Breaks Tolerance toward Intact  345(IV) Collagen, Eliciting Novel Anti-Glomerular Basement Membrane Autoantibodies Specific for  345NC1 Hexamers
  97. Deficiency of Annexin A1 in CD4+ T Cells Exacerbates T Cell-Dependent Inflammation
  98. Multiphoton imaging reveals a new leukocyte recruitment paradigm in the glomerulus
  99. Mast Cells Contribute to Peripheral Tolerance and Attenuate Autoimmune Vasculitis
  100. CD4+ Th1 cells are effectors in lupus nephritis—but what are their targets?
  101. The immunodominant myeloperoxidase T-cell epitope induces local cell-mediated injury in antimyeloperoxidase glomerulonephritis
  102. Mast cell activation and degranulation promotes renal fibrosis in experimental unilateral ureteric obstruction
  103. Endogenous Tim-1 (Kim-1) promotes T-cell responses and cell-mediated injury in experimental crescentic glomerulonephritis
  104. Amelioration of renal ischaemia-reperfusion injury by liposomal delivery of curcumin to renal tubular epithelial and antigen-presenting cells
  105. Endogenous Regulatory T Cells Adhere in Inflamed Dermal Vessels via ICAM-1: Association with Regulation of Effector Leukocyte Adhesion
  106. Renal Dendritic Cells Adopt a Pro-Inflammatory Phenotype in Obstructive Uropathy to Activate T Cells but Do Not Directly Contribute to Fibrosis
  107. Tim-1 promotes cisplatin nephrotoxicity
  108. Mast Cells Mediate Acute Kidney Injury through the Production of TNF
  109. Signal transducer and activation of transcription 6 (STAT6) regulates T helper type 1 (Th1) and Th17 nephritogenic immunity in experimental crescentic glomerulonephritis
  110. Interleukin-17A Promotes Early but Attenuates Established Disease in Crescentic Glomerulonephritis in Mice
  111. Endogenous foxp3+ T-regulatory cells suppress anti-glomerular basement membrane nephritis
  112. Toll-like receptor 2 induces Th17 myeloperoxidase autoimmunity while Toll-like receptor 9 drives Th1 autoimmunity in murine vasculitis
  113. The IL-27 Receptor Has Biphasic Effects in Crescentic Glomerulonephritis Mediated Through Th1 Responses
  114. The Emergence of Th17 Cells as Effectors of Renal Injury
  115. The Th17-Defining Transcription Factor ROR t Promotes Glomerulonephritis
  116. Intrinsic renal cell and leukocyte-derived TLR4 aggravate experimental anti-MPO glomerulonephritis
  117. TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy
  118. Toll-Like Receptor 9 Enhances Nephritogenic Immunity and Glomerular Leukocyte Recruitment, Exacerbating Experimental Crescentic Glomerulonephritis
  119. Platelet Recruitment to the Inflamed Glomerulus Occurs via an αIIbβ3/GPVI-Dependent Pathway
  120. Molecular Architecture of the Goodpasture Autoantigen in Anti-GBM Nephritis
  121. Lymphocytes promote albuminuria, but not renal dysfunction or histological damage in a mouse model of diabetic renal injury
  122. Review Article: Review: T helper 17 cells: Their role in glomerulonephritis
  123. Th17 Cells Promote Autoimmune Anti-Myeloperoxidase Glomerulonephritis
  124. Corrigendum
  125. Th1 and Th17 Cells Induce Proliferative Glomerulonephritis
  126. Atorvastatin enhances humoral immune responses but does not alter renal injury in experimental crescentic glomerulonephritis
  127. Review article: Kidney dendritic cells: Their role in homeostasis, inflammation and transplantation
  128. Endogenous CD100 promotes glomerular injury and macrophage recruitment in experimental crescentic glomerulonephritis
  129. IL-1RI deficiency ameliorates early experimental renal interstitial fibrosis
  130. Antimyeloperoxidase antibodies rapidly induce  4-integrin-dependent glomerular neutrophil adhesion
  131. IL-23, not IL-12, Directs Autoimmunity to the Goodpasture Antigen
  132. Kidney Research
  133. Targeting renal macrophage accumulation via c-fms kinase reduces tubular apoptosis but fails to modify progressive fibrosis in the obstructed rat kidney
  134. Advances in the pathogenesis of Goodpasture's disease: From epitopes to autoantibodies to effector T cells
  135. The tumour suppressor gene p53 modulates the severity of antigen-induced arthritis and the systemic immune response
  136. Targeting Leukocytes in Immune Glomerular Diseases
  137. The cytoplasmic domain of tissue factor in macrophages augments cutaneous delayed-type hypersensitivity
  138. Intrarenal Antigens Activate CD4+ Cells via Co-stimulatory Signals from Dendritic Cells
  139. T-bet Deficiency Attenuates Renal Injury in Experimental Crescentic Glomerulonephritis
  140. A New Approach to Idiopathic Nephrotic Syndrome
  141. Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease
  142. Methods in Renal Research: A new section in Nephrology (Editorial)
  143. Endogenous Myeloperoxidase Promotes Neutrophil-Mediated Renal Injury, but Attenuates T Cell Immunity Inducing Crescentic Glomerulonephritis
  144. Chapter 3 Pathogenesis of Renal Disease: Cytokines and Other Soluble Factors
  145. CD100 Enhances Dendritic Cell and CD4+ Cell Activation Leading to Pathogenetic Humoral Responses and Immune Complex Glomerulonephritis
  146. Anti-Neutrophil Cytoplasmic Antibodies and Effector CD4+ Cells Play Nonredundant Roles in Anti-Myeloperoxidase Crescentic Glomerulonephritis
  147. Inducible Co-Stimulatory Molecule Ligand Is Protective during the Induction and Effector Phases of Crescentic Glomerulonephritis
  148. IL-18 is redundant in T-cell responses and in joint inflammation in antigen-induced arthritis
  149. The isolation and purification of biologically active recombinant and native autoantigens for the study of autoimmune disease
  150. A Pathogenetic Role for Mast Cells in Experimental Crescentic Glomerulonephritis
  151. 'Genetics and The Immune Response' Abstracts of the 35th Annual Scientific Meeting of the Australasian Society for Immunology and 14th International HLA & Immunogenetics Workshop
  152. Glomerulonephritis, Th1 and Th2: what's new?
  153. More Targeted Treatments for Lupus Nephritis: Is the Future (Nearly) Here?
  154. CD80 and CD86 costimulatory molecules regulate crescentic glomerulonephritis by different mechanisms
  155. Granulocyte Macrophage Colony-Stimulating Factor Expression by Both Renal Parenchymal and Immune Cells Mediates Murine Crescentic Glomerulonephritis
  156. Glomerular Expression of CD80 and CD86 Is Required for Leukocyte Accumulation and Injury in Crescentic Glomerulonephritis
  157. IL-12p40 and IL-18 in Crescentic Glomerulonephritis: IL-12p40 is the Key Th1-Defining Cytokine Chain, Whereas IL-18 Promotes Local Inflammation and Leukocyte Recruitment
  158. Experimental autoimmune Goodpasture's disease: A pathogenetic role for both effector cells and antibody in injury
  159. Endogenous IL-13 Limits Humoral Responses and Injury in Experimental Glomerulonephritis but Does Not Regulate Th1 Cell-Mediated Crescentic Glomerulonephritis
  160. Fibrin independent proinflammatory effects of tissuefactor in experimental crescentic glomerulonephritis
  161. Experimental Autoimmune Anti-Glomerular Basement Membrane Glomerulonephritis: A Protective Role for IFN- 
  162. Plasmin is not protective in experimental renal interstitial fibrosis1
  163. Contributions of IL-1  and IL-1  to Crescentic Glomerulonephritis in Mice
  164. The role of flow cytometric ANCA detection in screening for acute pauci-immune crescentic glomerulonephritis
  165. Intrinsic Renal Cell Expression of CD40 Directs Th1 Effectors Inducing Experimental Crescentic Glomerulonephritis
  166. Endogenous alpha2-antiplasmin does not enhance glomerular fibrin deposition or injury in glomerulonephritis
  167. Plasminogen Activator Inhibitor-1 Is a Significant Determinant of Renal Injury in Experimental Crescentic Glomerulonephritis
  168. Cytokines, T cells and proliferative glomerulonephritis
  169. Effects of CTLA4-Fc on glomerular injury in humorally-mediated glomerulonephritis in BALB/c mice
  170. Interleukin-10 inhibits experimental mesangial proliferative glomerulonephritis
  171. Oxidant stress is increased within the glomerulus in experimental diabetic nephropathy
  172. Endogenous interleukin-10 regulates Th1 responses that induce crescentic glomerulonephritis
  173. Chemokines as therapeutic targets in renal disease
  174. Immunopathogenesis of crescentic glomerulonephritis
  175. Th1 and Th2T helper cell subsets affect patterns of injury and outcomes in glomerulonephritis
  176. IL-12 directs severe renal injury, crescent formation and Th1 responses in murine glomerulonephritis
  177. Interleukin-4 deficiency enhances Th1 responses and crescentic glomerulonephritis in mice
  178. Plasminogen and Plasminogen Activators Protect against Renal Injury in Crescentic Glomerulonephritis
  179. Immune modulation with interleukin-4 and interleukin-10 prevents crescent formation and glomerular injury in experimental glomerulonephritis